title: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
abstract: One year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) resulted in significantly improved liver histology and virological and biochemical endpoints in comparison with lamivudine. Patients who received at least 3 years of cumulative entecavir therapy in phase 3 studies and a long-term rollover study and underwent long-term liver biopsy were evaluated for improvements in histological appearance. Sixty-nine patients [50 HBeAg-positive and 19 HBeAg-negative] receiving entecavir therapy underwent long-term liver biopsy (median time of biopsy = 6 years, range = 3-7 years). Histological improvement was analyzed for 57 patients who had adequate baseline biopsy samples, baseline Knodell necroinflammatory scores > or =2, and adequate long-term biopsy samples. At the time of long-term biopsy, all patients in the cohort had a hepatitis B virus DNA level <300 copies/mL, and 86% had a normalized alanine aminotransferase level. Histological improvement (> or =2-point decrease in the Knodell necroinflammatory score and no worsening of the Knodell fibrosis score) was observed in 96% of patients, and a > or =1-point improvement in the Ishak fibrosis score was found in 88% of patients, including all 10 patients with advanced fibrosis or cirrhosis at the phase 3 baseline.
  
  
  CONCLUSIONS
  The majority of nucleoside-naive patients with CHB who were treated with entecavir in this long-term cohort achieved substantial histological improvement and regression of fibrosis or cirrhosis.
authors.affiliation: Department of Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan. ttchang@mail.ncku.edu.tw
authors.forename: Ting-Tsung
authors.initials: TT
authors.lastname: Chang
authors.forename: Yun-Fan
authors.initials: YF
authors.lastname: Liaw
authors.forename: Shun-Sheng
authors.initials: SS
authors.lastname: Wu
authors.forename: Eugene
authors.initials: E
authors.lastname: Schiff
authors.forename: Kwang-Hyub
authors.initials: KH
authors.lastname: Han
authors.forename: Ching-Lung
authors.initials: CL
authors.lastname: Lai
authors.forename: Rifaat
authors.initials: R
authors.lastname: Safadi
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Lee
authors.forename: Waldemar
authors.initials: W
authors.lastname: Halota
authors.forename: Zachary
authors.initials: Z
authors.lastname: Goodman
authors.forename: Yun-Chan
authors.initials: YC
authors.lastname: Chi
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Robert
authors.initials: R
authors.lastname: Hindes
authors.forename: Uchenna
authors.initials: U
authors.lastname: Iloeje
authors.forename: Suzanne
authors.initials: S
authors.lastname: Beebe
authors.forename: Bruce
authors.initials: B
authors.lastname: Kreter
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001706:Biopsy; D015331:Cohort Studies; D004279:DNA, Viral / Q000378:metabolism; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000821:virology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; C413685:entecavir; D006147:Guanine